Toms River, NJ, United States of America

Philip C Lang

This inventor holds 8 USPTO granted patents. Top assignees: Roberts Laboratories Inc., Shire US Inc., Dexgen Pharmaceuticals, Inc.. Active years: 1998-2003.

USPTO Granted Patents = 8

% Patents Active = 75.0

Average Co-Inventor Count = 1.3

ph-index = 6

Forward Citations = 110(Granted Patents)

Company Filing History:

3 out of 3

Roberts Laboratories Inc.

Dexgen Pharmaceuticals, Inc.

patents

Years Active: 1998-2003

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6653500 - Method for the manufacture of Anagrelide (2003-11-25),

2. 6583152 - Composition for reducing the risk or progression of cardiovascular diseases (2003-06-24),

3. 6541043 - Method and synergistic composition for treating attention deficit/hyperactivity disorder (2003-04-01),

4. 6479529 - Antioxidant stabilizer system for pharmaceutical formulations (2002-11-12),

5. 6388073 - Method for the manufacture of anagrelide (2002-05-14),

6. 6194420 - 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof (2001-02-27),

7. 5962488 - Stable pharmaceutical formulations for treating internal bowel syndrome (1999-10-05),

8. 5801245 - Process for the preparation of ethyl-N-(2,3 dichloro-6-nitrobenzyl) (1998-09-01),

Title: The Innovative Contributions of Philip C. Lang

Introduction

Philip C. Lang is a notable inventor based in Toms River, NJ, with a remarkable portfolio of eight patents. His work primarily focuses on advancements in pharmaceutical compositions and methods, showcasing his commitment to improving health outcomes.

Latest Patents

Among his latest patents is a method for the manufacture of Anagrelide. This patent outlines methods for producing Anagrelide base from 2,3-dichlorobenzaldehyde, including the creation of an intermediate compound, ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine. Additionally, it describes a cyclization method to form Anagrelide base from the corresponding iminoquinazoline compound. Another significant patent addresses a composition for reducing the risk or progression of cardiovascular diseases. This composition aims to decrease plasma homocysteine levels, which are linked to cardiovascular and other diseases. It includes dextromethorphan, folic acid, and vitamins B, providing a synergistic therapeutic effect. Other compositions he developed target conditions such as glaucoma and tardive dyskinesia, utilizing various beneficial ingredients.

Career Highlights

Philip C. Lang has worked with reputable companies, including Roberts Laboratories Inc. and Shire US Inc. His experience in these organizations has contributed to his innovative approach in the pharmaceutical field.

Collaborations

Throughout his career, Lang has collaborated with notable colleagues, including Roxanne P. Spencer and Wen-Lung Yeh. These partnerships have likely enhanced his research and development efforts.

Conclusion

Philip C. Lang's contributions to the field of pharmaceuticals through his patents and collaborations highlight his dedication to innovation and improving health outcomes. His work continues to impact the industry positively.